This report provides the most complete compilation of information about antibody-drug conjugate (ADC) companies, technologies and products in R&D. A comprehensive analysis of the state of the art and key trends guides the reader through this complex subject. Stakeholders in the field of antibody-drug conjugates are analyzed and their contribution to the growth ADC technology and products is assessed. A critical appraisal of the clinical results of active and discontinued ADC projects and products is provided. ADC technologies and products are challenged for their commercial value and growth potential.
Scope of the report:
• Drugs and Linkers Used in Antibody-Drug Conjugates
• Antibodies Used in Antibody-Drug Conjugates
• Analysis of Stakeholders in Antibody-Drug Conjugates
• Clinical Value of Antibody-Drug Conjugates
• R&D Pipeline Analysis of Antibody-Drug Conjugates
• Commercial Values of Antibody-Drug Conjugates
• Company Profiles
• Executive ADC Profiles
For more information and to purchase this Insight Pharma Report, visit: http://www.InsightPharmaReports.com
About Insight Pharma Reports
Insight Pharma Reports are written by experts in consulting and industry who collaborate with us to provide a series of reports that evaluate the salient issues in pharmaceutical technology, business, and therapy markets. Insight Pharma Reports are used by leading pharmaceutical, biotech, diagnostic, consulting, and financial companies to keep abreast of the latest advances in pharmaceutical R&D, their potential applications and business impacts, and their current and future position in the marketplace. Insight Pharma Reports is a division within Cambridge Healthtech Institute. http://www.InsightPharmaReports.com
Insight Pharma Reports offers our Affiliated Reports Collection which provides a repository of additional scientific and business resources. For more information, visit http://www.insightpharmareports.com/
# # #
Insight Pharma Reports are written by experts in consulting and industry who collaborate with us to provide a series of reports that evaluate the salient issues in pharmaceutical technology, business, and therapy markets.